BRPI0513155A - mutagênese por inserção para desenvolver polipeptìdeos alterados com propriedades realçadas - Google Patents
mutagênese por inserção para desenvolver polipeptìdeos alterados com propriedades realçadasInfo
- Publication number
- BRPI0513155A BRPI0513155A BRPI0513155-3A BRPI0513155A BRPI0513155A BR PI0513155 A BRPI0513155 A BR PI0513155A BR PI0513155 A BRPI0513155 A BR PI0513155A BR PI0513155 A BRPI0513155 A BR PI0513155A
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- amino acids
- libraries
- amino acid
- function
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
MUTAGéNESE POR INSERçãO PARA DESENVOLVER POLIPEPTìDEOS ALTERADOS COM PROPRIEDADES REALçADAS. Um método de mutagênese pelo qual um aminoácido predeterminado é introduzido em cada e toda posição de um conjunto selecionado de posições em uma região pré selecionada (ou várias regiões diferentes) de um polipeptídeo para produzir uma biblioteca de análogos de polipeptídeo é divulgado. O método é fundamentado no local que certos aminoácidos desempenham um papel crucial na estrutura e função das proteínas e assim é capaz de identificar e distinguir os resíduos de aminoácido funcionais ("zonas quentes") de resíduos de aminoácidos não funcionais ("zonas frias") dentro de um polipeptídeo ou porção deste. As bibliotecas podem ser geradas que contêm apenas análogos de polipeptídeo desejados e são de tamanho razoável para a triagem. As bibliotecas podem ser usadas para estudar o papel de aminoácidos específicos na estrutura e função do polipeptídeo e para desenvolver polipeptideos novos ou melhorados tais como anticorpos, fragmentos de anticorpo, anticorpos de cadeia simples, enzimas, e ligandos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58591804P | 2004-07-06 | 2004-07-06 | |
US60/585,918 | 2004-07-06 | ||
PCT/US2005/024140 WO2006023144A2 (en) | 2004-07-06 | 2005-07-06 | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0513155A true BRPI0513155A (pt) | 2008-04-29 |
BRPI0513155B1 BRPI0513155B1 (pt) | 2021-07-20 |
Family
ID=35968026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513155-3A BRPI0513155B1 (pt) | 2004-07-06 | 2005-07-06 | Método de distinguir um ou mais resíduos de aminoácido funcionais dos resíduos de aminoácido não-funcionais em uma região definida dentro de um polipeptídeo, método de gerar uma biblioteca de análogos de polipeptídeo e método de identificar um subconjunto de análogos de polipeptídeo tendo uma propriedade desejada |
Country Status (9)
Country | Link |
---|---|
US (1) | US9012369B2 (pt) |
EP (1) | EP1774019B1 (pt) |
JP (2) | JP4939410B2 (pt) |
AT (1) | ATE528396T1 (pt) |
BR (1) | BRPI0513155B1 (pt) |
CA (1) | CA2572917C (pt) |
ES (1) | ES2372503T3 (pt) |
MX (1) | MX2007000105A (pt) |
WO (1) | WO2006023144A2 (pt) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
WO2007127290A2 (en) * | 2006-04-24 | 2007-11-08 | Protelix, Inc. | Method for producing viral vaccine and therapeutic peptide antigens |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
EP2118281A2 (en) | 2007-02-12 | 2009-11-18 | Codexis, Inc. | Structure-activity relationships |
EP2392653B1 (en) * | 2007-07-12 | 2014-03-19 | New England Biolabs, Inc. | High fidelity restriction endonucleases |
EP4368721A2 (en) | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
US9688762B2 (en) | 2007-09-26 | 2017-06-27 | Chugai Sciyaku Kabushiki Kaisha | Modified antibody constant region |
WO2009041621A1 (ja) * | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗il-6レセプター抗体 |
JP2011504740A (ja) | 2007-11-27 | 2011-02-17 | アブリンクス エン.ヴェー. | ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド |
US20110118447A1 (en) * | 2007-12-31 | 2011-05-19 | Xoma Technology Ltd. | Methods and materials for targeted affinity enhancement |
NO2708559T3 (pt) | 2008-04-11 | 2018-08-25 | ||
CN102076713B (zh) | 2008-05-02 | 2015-03-25 | 诺华股份有限公司 | 改进的基于纤连蛋白的结合分子及其用途 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
WO2010111707A1 (en) | 2009-03-27 | 2010-09-30 | Sapphire Energy, Inc. | Variant isoprenoid producing enzymes and uses thereof |
CN105399828B (zh) | 2009-04-10 | 2021-01-15 | 埃博灵克斯股份有限公司 | 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽 |
US10618964B2 (en) | 2009-04-10 | 2020-04-14 | Ablynx N.V. | Nanobody against IL-6R |
NZ597314A (en) | 2009-06-05 | 2013-07-26 | Ablynx Nv | Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
SG187225A1 (en) | 2010-07-30 | 2013-02-28 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
CN103339145A (zh) * | 2010-09-22 | 2013-10-02 | 安姆根有限公司 | 运载体免疫球蛋白及其用途 |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
AU2012311443B2 (en) | 2011-09-23 | 2016-12-01 | Ablynx Nv | Prolonged inhibition of interleukin-6 mediated signaling |
BR112014008804A2 (pt) | 2011-10-11 | 2017-06-13 | Medimmune Llc | suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos |
CN104080909A (zh) | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
AU2013224851B2 (en) | 2012-03-02 | 2018-03-01 | Ablynx Nv | Pseudomonas aeruginosa PcrV binding single variable domain antibodies |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
EP2949789B1 (en) * | 2013-01-24 | 2021-07-28 | AbTLAS Co., Ltd. | Protein combination-based fv library, and preparation method therefor |
EP2989202B1 (en) | 2013-04-25 | 2019-04-10 | Sutro Biopharma, Inc. | The use of lambda-gam protein in ribosomal display technology |
US20160069897A1 (en) * | 2013-04-25 | 2016-03-10 | Suthro Biopharma, Inc. | Selection of fab fragments using ribosomal display technology |
US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
PL3030682T3 (pl) | 2013-08-05 | 2020-11-16 | Twist Bioscience Corporation | Biblioteki genowe syntezowane de novo |
US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
JP2017534617A (ja) | 2014-10-21 | 2017-11-24 | アブリンクス エン.ヴェー. | Il−6r関連疾患の処置 |
WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
PL3263132T3 (pl) | 2015-02-27 | 2024-04-15 | Chugai Seiyaku Kabushiki Kaisha | Kompozycja do leczenia chorób związanych z il-6 |
KR20240093725A (ko) | 2015-03-12 | 2024-06-24 | 메디뮨 엘엘씨 | 알부민 융합 단백질의 정제 방법 |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
JP6875683B2 (ja) | 2015-05-19 | 2021-05-26 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症(ms)患者の新規治療適用判断方法 |
JP6867302B2 (ja) | 2015-05-21 | 2021-04-28 | フル スペクトラム ジェネティクス, インコーポレイテッド | タンパク質の特徴を改善する方法 |
KR20180050411A (ko) * | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
CN115920796A (zh) | 2015-12-01 | 2023-04-07 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
USD782516S1 (en) | 2016-01-19 | 2017-03-28 | Apple Inc. | Display screen or portion thereof with graphical user interface |
AU2017315294B2 (en) | 2016-08-22 | 2023-12-21 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
JP6871364B2 (ja) | 2016-09-21 | 2021-05-12 | ツイスト バイオサイエンス コーポレーション | 核酸に基づくデータ保存 |
US10907274B2 (en) | 2016-12-16 | 2021-02-02 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
JP2020508661A (ja) | 2017-02-22 | 2020-03-26 | ツイスト バイオサイエンス コーポレーション | 核酸ベースのデータ保存 |
WO2018170169A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
KR102628876B1 (ko) | 2017-06-12 | 2024-01-23 | 트위스트 바이오사이언스 코포레이션 | 심리스 핵산 어셈블리를 위한 방법 |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
KR20200047706A (ko) | 2017-09-11 | 2020-05-07 | 트위스트 바이오사이언스 코포레이션 | Gpcr 결합 단백질 및 이의 합성 방법 |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
CA3088911A1 (en) | 2018-01-04 | 2019-07-11 | Twist Bioscience Corporation | Dna-based storage device and method for synthesizing polynucleotides using the device |
AU2019270243A1 (en) | 2018-05-18 | 2021-01-07 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
AU2020229349A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
CA3131691A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
WO2021061829A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2079802C (en) * | 1990-04-05 | 2001-09-18 | Roberto Crea | Walk-through mutagenesis |
AU1456101A (en) | 1999-11-03 | 2001-05-14 | Maxygen, Inc. | Antibody diversity generation |
JP2003516755A (ja) * | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
US20040033569A1 (en) | 2002-04-17 | 2004-02-19 | Roberto Crea | "Doping" in walk-through mutagenesis |
CA2482863A1 (en) | 2002-04-17 | 2003-10-30 | Roberto Crea | Universal libraries for immunoglobulins |
ES2609102T3 (es) * | 2003-06-27 | 2017-04-18 | Bioren, LLC | Mutagénesis por revisión |
-
2005
- 2005-07-06 ES ES05809866T patent/ES2372503T3/es active Active
- 2005-07-06 US US11/571,088 patent/US9012369B2/en active Active
- 2005-07-06 CA CA2572917A patent/CA2572917C/en active Active
- 2005-07-06 AT AT05809866T patent/ATE528396T1/de not_active IP Right Cessation
- 2005-07-06 MX MX2007000105A patent/MX2007000105A/es active IP Right Grant
- 2005-07-06 EP EP05809866A patent/EP1774019B1/en active Active
- 2005-07-06 WO PCT/US2005/024140 patent/WO2006023144A2/en active Application Filing
- 2005-07-06 JP JP2007520506A patent/JP4939410B2/ja active Active
- 2005-07-06 BR BRPI0513155-3A patent/BRPI0513155B1/pt active IP Right Grant
-
2011
- 2011-09-15 JP JP2011201518A patent/JP2012041347A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2006023144A2 (en) | 2006-03-02 |
US9012369B2 (en) | 2015-04-21 |
CA2572917A1 (en) | 2006-03-02 |
EP1774019A4 (en) | 2009-05-20 |
JP4939410B2 (ja) | 2012-05-23 |
JP2008505642A (ja) | 2008-02-28 |
MX2007000105A (es) | 2007-07-18 |
JP2012041347A (ja) | 2012-03-01 |
EP1774019B1 (en) | 2011-10-12 |
ATE528396T1 (de) | 2011-10-15 |
CA2572917C (en) | 2012-04-03 |
BRPI0513155B1 (pt) | 2021-07-20 |
WO2006023144A3 (en) | 2006-08-17 |
EP1774019A2 (en) | 2007-04-18 |
ES2372503T3 (es) | 2012-01-20 |
US20080214406A1 (en) | 2008-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513155A (pt) | mutagênese por inserção para desenvolver polipeptìdeos alterados com propriedades realçadas | |
WO2005003345A3 (en) | Look-through mutagenesis | |
ES2078518T3 (es) | Mutagenesis por desplazamiento completo. | |
Tu et al. | Sequence analysis and molecular docking of antithrombotic peptides from casein hydrolysate by trypsin digestion | |
Camporeale et al. | K8 and K12 are biotinylated in human histone H4 | |
Wong et al. | Global analysis of posttranslational protein arginylation | |
WO2003099999A3 (en) | Generation and selection of protein library in silico | |
Lai et al. | The emerging role of the peptidome in biomarker discovery and degradome profiling | |
DK1534830T3 (da) | In vito-peptid-ekspressionsbibliotek | |
ATE508361T1 (de) | Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie | |
WO2002042427A3 (en) | Mass tags for quantitative analysis | |
JP2019507341A5 (pt) | ||
WO2002086081A3 (en) | Methods and systems for identifying proteins | |
Fu et al. | rMCP-2, the major rat mucosal mast cell protease, an analysis of its extended cleavage specificity and its potential role in regulating intestinal permeability by the cleavage of cell adhesion and junction proteins | |
DE60109490D1 (de) | Umgekehrtes labelierungsverfahren zur schnellen identifikation von marker/ziel-proteinen | |
Dørum et al. | Gluten-specific antibodies of celiac disease gut plasma cells recognize long proteolytic fragments that typically harbor T-cell epitopes | |
WO2005010023A3 (en) | Method for prediction of an epitope | |
ATE223971T1 (de) | Neue methoden zum auffinden von liganden- und ziel-biomolekülen | |
WO2006024875A3 (en) | Method for determinig protein solubility | |
SE0302559D0 (sv) | Method | |
DE50105263D1 (de) | Verfahren zur analyse von proteinen | |
ATE327251T1 (de) | Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen | |
WO2006086288A3 (en) | Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells | |
Lancrajan et al. | Absolute quantification of DcR3 and GDF 15 from human serum by LC‐ESI MS | |
WO2003073351A3 (en) | Screening process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/07/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |